Leaderboards/PI3K/AKT/mTOR signaling in cancer

PI3K/AKT/mTOR signaling in cancer

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Tianhua Yan
China Pharmaceutical University
89
2
Yuan Fang
Key Laboratory of Guangdong Province
82
3
Alicia Okines
Royal Marsden NHS Foundation Trust
67
4
Zhenjie Wang
First Affiliated Hospital of Bengbu Medical College
66
5
Mohamed M. Abdel‐Daim
Suez Canal University
66
6
Jinhui Zou
Wuhan Union Hospital
64
7
Brett S. Carver
Memorial Sloan Kettering Cancer Center
62
8
Jie Zhao
First Affiliated Hospital of Zhengzhou University
61
9
Song Ming
Wuhan Third Hospital
60
10
Stephen T. Oh
Washington University in St. Louis
60

Rising Stars Papers

1
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
Nature Communications|2025
12 cit.
2
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Blood Cancer Journal|2024
7 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Martin S. Taylor
Harvard University
99
2
Shokoofeh Jamshidi
Hamedan University of Medical Sciences
99
3
Xufeng Yao
Anhui Medical University
95
4
Abbas Asoudeh-Fard
Tabriz University of Medical Sciences
85
5
A. H. Shaikat
International Islamic University Chittagong
84
6
Despina Michailidou
Columbia University
77
7
Kangping Yang
Nanchang University
66
8
Xiong Shu
Peking University
62
9
Chunli Wen
Shandong University
58
10
Yadong Guo
Tongji University
58

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
David M. Sabatini
Howard Hughes Medical Institute
99
2
Xuejun Jiang
Memorial Sloan Kettering Cancer Center
98
3
Richard A. Miller
University of Michigan
96
4
Seishi Ogawa
Kyoto University
93
5
Rafi Ahmed
Emory Healthcare
81
6
José Baselga
Novartis (Switzerland)
79
7
Alessandra Mosca
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
77
8
Guanghui Wang
Zaozhuang Municipal Hospital
76
9
Charles Swanton
Cancer Research UK
72
10
Viorel Jinga
Carol Davila University of Medicine and Pharmacy
69

All-Time Leaders Papers

1
mTOR signaling at a glance
Journal of Cell Science|2009
2.1k cit.
2
Ferroptosis is an autophagic cell death process
Cell Research|2016
1.8k cit.
3
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
New England Journal of Medicine|2015
1.7k cit.
4
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Nature|2011
1.7k cit.
5
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
Genome biology|2016
1.3k cit.
6
Intratumor Heterogeneity: Evolution through Space and Time
Cancer Research|2012
926 cit.
7
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Cell|2021
875 cit.
8
Resolving genetic heterogeneity in cancer
Nature Reviews Genetics|2019
689 cit.
9
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology|2011
684 cit.
10
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
Cell|2023
638 cit.

Reagents for PI3K/AKT/mTOR signaling in cancer

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

PTEN (138G6) Rabbit Monoclonal Antibody

Cited in 33 papers
#9559$152
View Evidence →Cell Signaling Technology

Phospho-AMPK alpha (Thr172) (40H9) Rabbit Monoclonal Antibody (Biotinylated)

Cited in 25 papers
#5256$587
View Evidence →Cell Signaling Technology

Phospho-WIPI2 (Ser413) Antibody

Cited in 25 papers
#13571$362
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

TFIIE-alpha Antibody

Cited in 54 papers
#13375$317
View Evidence →Cell Signaling Technology

PSMG1/PAC1 Antibody

Cited in 47 papers
#13378$317
View Evidence →Cell Signaling Technology

Cas9 (S. aureus) (6H4) Mouse Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 43 papers
#10314$465
View Evidence →